Siemens names electromedical VP
Siemens Medical Systems has appointed Michael A. Bunnell vice president of sales and marketing for the company’s electromedical systems division. Bunnell succeeds Tim O’Malley, who left the Issaquah, WA-based company. Bunnell will oversee sales
Siemens Medical Systems has appointed Michael A. Bunnell vice president of sales and marketing for the companys electromedical systems division. Bunnell succeeds Tim OMalley, who left the Issaquah, WA-based company. Bunnell will oversee sales and marketing of the electromedical divisions critical-care and cardiology products. Products in the electromedical division include patient monitors, anesthesia equipment, and other critical-care equipment. Bunnell joins Siemens after a 24-year career at Hewlett-Packard, where he held many senior sales and marketing management positions, including general manager of the companys clinical information software program.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
